← FDA DRUG APPROVALS

FDA ANDA · ANDA206398

VORICONAZOLE

Sponsor: ALMAJECT

APPLICATION
ANDA206398
TYPE
ANDA
ORIGINAL APPROVAL
2016-03-23
LATEST ACTION
2025-07-09
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

VORICONAZOLEDiscontinued
VORICONAZOLE 200MG/VIAL · POWDER · INTRAVENOUS

Approval history

2025-07-09Labeling · Supplement 8 · standardAP
2023-02-02Labeling · Supplement 7 · standardAP
2023-02-02Labeling · Supplement 6 · standardAP
2021-07-02Labeling · Supplement 5 · standardAP
2021-07-02Labeling · Supplement 1 · standardAP
2016-03-23UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →